Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Diabetes is the fifth leading cause of death across most developed countries, and is becoming an increasingly larger issue in developing nations. Since 1983, the Journal of Labor Economics has presented international research that examines issues affecting the economy as well as social and private behavior. With a focus on Type I diabetes, the company holds more than 7% of the underpenetrated U.S. This has led to strong commercial interest in the development of T2DM therapeutics. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Type 2 diabetics can take oral drugs, but over time most end up needing insulin injections to control their disease.
The risks of type 2 diabetes include high blood pressure, advancing age, obesity, history of gestational diabetes, family history of diabetes, poor nutrition during pregnancy, physical inactivity, and impaired glucose tolerance. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. It usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. Novo’s Tresiba competes with GlaxoSmithKline’s (GSK) Tanzeum, Sanofi’s (SNY) Toujeo and Lantus, and Eli Lilly’s (LLY) Basalgar. About Reimbursement Tracker iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States. and How Tresiba and Xultophy Will Drive Novo’s Performance. The contribution from the GLP-1 class is increasing steadily.
Find the diabetes market size from 2016-2026. The details of GLP-1 class are available at Novo Nordisk’s Victoza Maintains Leadership in GLP-1 Market. Gaby Lapera: What’s really interesting is that in 2012, at least in the U.S., the CDC estimated that around 30% of people who had diabetes weren’t diagnosed with diabetes yet. Factors triggering diabetes in Asian countries with high population such as India and China are the rapid urbanization, drastic change in lifestyle of people – most follow a static lifestyle. To avoid such risk, ETFs are a good option. To get exposure to Novo Nordisk Pharmaceuticals and control excessive company-specific risks, investors can choose to invest in the PowerShares International Dividend Achievers Portfolio (PID). Novo Nordisk accounts for 0.41% of PID’s total holdings.